CD274 and nonpapillary renal cell carcinoma: Immune checkpoint blockade of PD-1 and its ligand PD-L1 have been implemented in advanced lung, renal (CCRCC) and bladder carcinomas, as well as in melanoma, with promising results in several trials [9,10].